EC approves Bristol-Myers Squibb’s Sprycel in combination with chemotherapy for Ph+ALL
Bristol-Myers Squibb announced the EC has approved Sprycel (dasatinib) in combination with chemotherapy for treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. This is the second pediatric leukemia indication for Sprycel in Europe. February 11, 2019